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Abstract
Pax6 is a transcription factor important for early embryo development. It is expressed in several cancer cell lines and tumors.
In glioblastoma, PAX6 has been shown to function as a tumor suppressor. Dickkopf 3 (Dkk3) is well established as a tumor
suppressor in several tumor types, but not much is known about the regulation of its expression. We have previously found
that Pax6 and Pax6(5a) increase the expression of the Dkk3 gene in two stably transfected mouse fibroblast cell lines. In this
study the molecular mechanism behind this regulation is looked at. Western blot and reverse transcriptase quantitative PCR
(RT-qPCR) confirmed higher level of Dkk3 expression in both Pax6 and Pax6(5a) expressing cell lines compared to the
control cell line. By the use of bioinformatics and electrophoretic mobility shift assay (EMSA) we have mapped a functional
Pax6 binding site in the mouse Dkk3 promoter. The minimal Dkk3 promoter fragment required for transcriptional activation
by Pax6 and Pax6(5a) was a 200 bp region just upstream of the transcriptional start site. Mutation of the evolutionary
conserved binding site in this region abrogated transcriptional activation and binding of Pax6/Pax6(5a) to the mouse Dkk3
promoter. Since the identified Pax6 binding site in this promoter is conserved, RT-qPCR and Western blot were used to look
for regulation of Dkk3/REIC expression in human cell lines. Six of eight cell lines tested showed changes in Dkk3/REIC
expression after PAX6 siRNA knockdown. Interestingly, we observed that the Pax6/Pax6(5a) expressing mouse fibroblast cell
lines were less responsive to canonical Wnt pathway stimulation than the control cell line when TOP/FOP activity and the
levels of active b-catenin and GSK3-b Ser9 phosphorylation were measured after LiCl stimulation.
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Introduction
Pax6 belongs to the paired box family of transcription factors,
and plays an important role in the development of the central
nervous system, the eyes, the nose and the pancreas (reviewed in
[1]). Pax6 has two DNA binding domains called the paired
domain and the paired-type homeodomain [2,3], which can also
participate in protein-protein interactions [4]. The transcriptional
activation domain is located C-terminally, and has been shown to
be a target of the Erk1/2 and p38 MAP kinases [5]. The Pax6(5a)
isoform is characterized by a 14 amino acid insertion in the N-
terminal part of the paired domain. This insertion changes the
DNA binding specificity of the Pax6 paired domain from the
consensus primarily recognized by a single paired domain [6], to a
consensus looking like two tandem repeats, preferably bound by
four Pax6(5a) paired domains simultaneously [2,7]. Both Pax6
isoforms are expressed together in various tissues in the eye and
brain, and seem to interact functionally to stimulate transcription
of target genes [8]. However, when stably transfected and
expressed in FlpIn-3T3 cell lines, the Pax6- and Pax6(5a) isoforms
are able to regulate gene expression independently, with both
common and isoform specific target genes [9]. An increasing
number of Pax6 target genes relevant for the development and
function of the brain, eyes and pancreas have been reported over
the years, both based on functional studies and gene expression
microarrays. Recently, an extensive analysis with combinations of
ChIP-chip and gene expression microarrays identified more than
5000 promoters and about 10 different Pax6 binding motifs
occupied by PAX6 in three different tissues (forebrain, lens and
pancreatic b–cells). Around 1000 of these were occupied in two
tissues, and 131 in all three tissues [10]. In addition to its
important role in embryo development, Pax6 is expressed in
several tumors of the brain, pancreas and eye [11–13]. A link
between the Wnt pathway and Pax6 is reported both in the brain
[14], in the lens [15] and in the cornea [16].
The Wnt signaling pathway is important for normal embryo-
genesis, but is also reported to participate in tissue regeneration,
neurodegenerative disease development and cancer progression
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(reviewed in [17]). The canonical Wnt pathway involves signaling
molecules binding to the frizzled receptor and the LRP5/6 co-
receptors, generating a signaling cascade that ultimately leads to
the stabilization of b–catenin. b-catenin translocates to the
nucleus, interacts with transcription factors from the Tcf/LEF
family, and activates transcription by replacing repressor com-
plexes like Groucho (reviewed in [18]). The Dickkopf family is a
family of secreted factors (Dkk1–4) that interfere with the Wnt
signaling pathway. Dkk1, Dkk2 and Dkk4 function as inhibitors of
the canonical Wnt pathway by binding the LPR5/6 receptors and
Kremen1/2 (Krm 1/2) leading to internalization, which prevents
binding and activation by Wnt [19]. Dkk3 does not intereact with
Krm1, Krm2 and LRP6 on the cell surface [19,20]. It can
however interact with the Krm receptor intracellularly to promote
Wnt signaling [20]. There are reports on Dkk3 both enhancing
and repressing the Wnt signaling pathway [20,21], but not much is
known about the mechanism. Dkk3 is downregulated and
considered to function as a tumor suppressor in a number of
tumor types [22,23]. However, for some tumors the downregu-
lation of Dkk3 is correlated with tumor progression [24,25].
Hypermethylation of the human Dkk3 promoter [26] may be the
mechanism for the downregulation in various tumour types, as is
repression of Dkk3 by the MYCN regulated miRNA-92 [27,28].
In addition, Dkk3 expression is restricted by chromatin modifica-
tions [29,30]. Nothing is known about individual transcription
factors regulating Dkk3 expression on the promoter level.
Here we show that Pax6 and Pax6(5a) regulate the expression of
Dkk3 in murine fibroblast cell lines stably transfected with either of
two Pax6 isoforms. RT-qPCR and Western blot show a higher
level of Dkk3 expression in both Pax6 and Pax6(5a) cell lines
compared to the control cell line. By the use of bioinformatics,
reporter gene assays and electrophoretic mobility shift assays we
have mapped a functional Pax6 binding site in the mouse Dkk3
promoter. This site is conserved in the human Dkk3/REIC
promoter, and RT-qPCR and Western blot indicate that PAX6
regulates Dkk3/REIC expression in human cell lines as well. The
FlpIn-3T3 Pax6 and -Pax6(5a) cell lines are less responsive to
canonical Wnt pathway stimulation than the control cell line.
Results
Dkk3 expression is upregulated in the FlpIn-3T3 Pax6-
and Pax6(5a) cell lines and the protein is localized in
cytoplasm and nucleus
In search for genes regulated by Pax6 we used mouse fibroblast
FlpIn-3T3 cells to generate two cell lines stably expressing either
the Pax6- or the Pax6(5a) isoform. Gene expression microarray
identified Dkk3 to be the gene strongest upregulated by Pax6(5a)
[9]. RT-qPCR verified the strong regulation, and Pax6 ChIP
confirmed direct binding of both Pax6 and Pax6(5a) to the Dkk3
promoter in the FlpIn-3T3 cell lines [9]. As shown in Fig. 1A,
Dkk3 expression is increased 24-fold in the Pax6(5a) cell line
compared to the control cell line. Also in the Pax6 expressing cell
line there is a 6-fold increase in expression of Dkk3. This
phenomenon was also observed on Western blots (Fig. 1B). The
difference between the observed (60–70 kD) and expected (38 kD)
molecular weight of Dkk3 can probably be explained by N-
glycosylation [37]. Depending on the cell type, Dkk3 is reported to
be secreted, localized in the cytoplasm in the perinuclear region
(most probably ER) or in the nucleus [38]. We made nuclear and
cytoplasmic extracts and confirmed expression of Dkk3 in both
compartments, in addition to the nuclear pellet (Fig. 1C). We also
observed secreted Dkk3 in conditioned media from all the FlpIn-
3T3 cell lines (data not shown). Immunostaining of fixed FlpIn-
3T3 cell lines confirmed Dkk3 localization in the cytoplasm and
nucleus of all three cell lines (Fig. 1D), with the strongest
expression in the Pax6(5a) cell line, followed by the Pax6 cell line.
Dkk3/REIC3 expression is regulated by PAX6 in several
human cell lines
To see whether Pax6 regulates expression of Dkk3 in other cell
types in addition to the FlpIn-3T3 Pax6- and Pax6(5a) cell lines,
several human cancer cell lines were investigated. When PAX6
was knocked down by stably transfected PAX6 shRNA in
pancreatic adenocarcinoma HPAFII cells, a 4-fold decrease in
Dkk3/REIC gene expression was observed (Fig. 2A). A similar
result was obtained by transiently transfecting HPAFII cells with
siRNA (data not shown). The expression decrease was confirmed
by Western blot (Fig. 2B). However, for the lung cancer cell lines
NCI-H661 and NCI-H640, the glioblastoma cell line GaMG and
the prostate cancer cell line PC3, PAX6 knockdown by siRNA
resulted in an increased Dkk3 expression, indicating that
endogenous PAX6 repressed Dkk3 expression in these cancer cell
lines. This was also observed for the normal human lens epithelial
cell line B3 (Fig. 2A and 2C). PAX6 knockdown did not influence
DKK3 expression in the HeLa (human cervix carcinoma) or U-87
(human glioblastoma) cell lines (results not shown). To summarize,
this shows that regulation of Dkk3 by PAX6 takes place in several
human tissues and cell lines in a context-specific manner, resulting
in either up- or downregulation of Dkk3 gene expression.
Predicted Pax6 binding sites are conserved between the
mouse and human Dkk3 promoters
To our knowledge there are no publications on transcription
factors binding to the Dkk3 promoter. According to the Database
for Transcriptional Startsites (DBTSS) there are two promoter
regions in the mouse, and three in the human Dkk3 gene [36]. The
distance between these promoters is approximately 620 bp in
mouse and 740 bp (first and last promoter) in humans. In both
species the promoters are GC-rich regions with no TATA box
present. Transcription starts within a region of 50 bp for each
promoter. From here on the two clusters of transcriptional start
sites will be called TSS-1 and TSS-2. Alignment of the human-
and mouse Dkk3 promoter shows conservation only around TSS-
2, where 77% identicality was observed over a region of 374
basepairs (see alignment in Fig. 2D). When analysed by rVista [39]
two evolutionary conserved Pax6 binding sites were identified in
this region. Evolutionary conserved binding sites for BSAP (Pax5)
were also identified using the ConSite database [40]. Three BSAP
sites (two for human) overlapped just 59 of TSS-2 in the mouse
Dkk3 gene. Since BSAP and Pax6 binding sites’ preferences only
differ by 1 nucleotide, and since Pax6 is able to bind the BSAP
binding site [41], we considered the identified BSAP sites as
possible Pax6 binding sites. The Findpatterns function of the
Accelrys GCG software was then used to look for potential
Pax6(5a) binding sites [2] in the mouse- and human Dkk3
promoter (see materials and methods). One site was identified
approximately 200 bp downstream of TSS-2 in the mouse Dkk3
promoter. Interestingly, a 5aCON halfsite was also found in the
human DKK3 promoter, starting just 39 to the 5aCON halfsite
identified in the mouse sequence of this evolutionary conserved
region. In each species the 5aCON halfsite is therefore part of an
incomplete (not optimal) full 5aCON site. In addition, this site
overlaps with the evolutionary conserved Pax6 binding site
identified by rVista (Fig. 2D).
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Both Pax6 and Pax6(5a) are capable of activating
transcription from a 792 bp cloned fragment of the
mouse Dkk3 promoter
To test if the bioinformatically predicted Pax6 binding sites
were functional in transcriptional regulation, we cloned a fragment
of the mouse Dkk3 promoter containing the conserved Pax6
binding sites close to TSS-2. Approximately 600 bp upstream- and
200 bp downstream of TSS-2 were cloned into the pGL3-basic
reporter gene vector (Fig. 3A). We first tested the cloned Dkk3
promoter by transient transfection and reporter gene assays in the
three FlpIn-3T3 cell lines. The cloned Dkk3 promoter showed
slightly higher activity in the FlpIn-3T3 Pax6(5a) cells compared to
the FlpIn-3T3 control or -Pax6 cells (Fig. 3B), which fits with the
RT-qPCR and WB data (Fig. 1A and 1B). However, based on the
RT-qPCR results, a bigger difference in Dkk3 promoter activity
was expected. The relatively weak activation of the cloned Dkk3
promoter in the FlpIn-3T3 Pax6(5a) cells indicated that TSS-1,
additional sequences surrounding the TSS-2, or enhancers acting
from more distal positions, were required for full transcriptional
activity of the Dkk3 promoter in this cell line.
Further studies of the cloned mouse Dkk3 promoter were done
in HeLa cells. By itself the cloned Dkk3 promoter fragment had
little activity. However, co-transfection with either mouse Pax6- or
Pax(5a)-expressing plasmids caused 6–12 fold increase in tran-
scriptional activity, with Pax6 being more efficient than Pax6(5a)
in transcriptional activation (Fig. 3C). The evolutionary conserved
BSAP- and Pax6/Pax6(5a) binding sites are situated on each side
of the TSS-2, with a naturally occurring PstI site in between
(Fig. 3A). Deletions from both ends of the promoter by use of the
internal SacI and PstI sites gradually decreased the transcriptional
activity obtained by co-transfected Pax6 and Pax6(5a) (Fig. 3C).
However, a 184 bp region just upstream of the TSS-2 (2193/29)
was still capable of responding to co-transfected Pax6 and
Pax6(5a). This region of the Dkk3 promoter contained the
predicted BSAP binding sites. Remarkably, the removal of the
39 end of the promoter construct (containing the predicted Pax6/
Pax6(5a) binding site) decreased the effect of co-transfected Pax6
but not the effect of co-transfected Pax6(5a) (Fig. 3C, compare
constructs 1 and 4). While Pax6 was most efficient in activating
transcription from the longest Dkk3 promoter construct, Pax6(5a)
caused the highest transcriptional activity from the 184 bp
construct (Fig. 3C, compare construct 1 with 4 and 6). Similar
results were obtained when the mouse Dkk3 promoter constructs
were transfected into the murine FlpIn-3T3 control cell line,
indicating that there are no species specific differences in the
regulation of the cloned promoter fragment (Fig. 3D).
EMSA confirms binding of Pax6 to elements in the mouse
Dkk3 promoter
To verify whether the predicted BSAP, Pax6 and Pax6(5a)
binding sites in the mouse Dkk3 promoter directly bind Pax6 and
Pax6(5a), EMSA was performed. Purified recombinant GST-Pax6
paired domain (PD) proteins (with and without the amino acids
encoded by the exon 5a insert) were mixed with a radiolabeled
oligonucleotide identical to the 50 bp covering the three overlap-
ping BSAP sites (Fig. 4A). The recombinant Pax6 PD bound the
BSAP site well, while a mutated version of this probe was bound
less efficiently (Fig. 4A). The recombinant GST-Pax6(5a) PD was
not able to bind to the BSAP site probe, which was expected since
this probe is not similar to the Pax6(5a) binding site consensus.
Puzzling results were obtained with the probe for the predicted
Pax6/Pax6(5a) binding site downstream of TSS-2. This probe
(named ‘‘5aCON’’ in Fig. 4A) was not bound at all, or bound very
weakly, by the recombinant GST-Pax6(5a) PD. However, GST-
Pax6 PD was able to bind the ‘‘5aCON’’ probe, but less efficiently
than it did with both the optimized (OPT) and mutated (MUT)
versions of this probe (Fig. 4A). The result of the EMSA with
regard to the ‘‘BSAP’’ probe is in line with the results of the
reporter gene assay shown in Fig. 3C, where the predicted BSAP
binding site in the Dkk3 promoter is located in the 184 bp
fragment still able to respond to co-transfected Pax6 (construct 6,
Fig. 3C). When the ‘‘BSAP’’ binding site mutation was introduced
into this minimal 184 bp mDkk3 promoter vector co-transfected
Pax6 could no longer activate transcription in HeLa cells (Fig. 4C).
The ‘‘BSAP’’ mutation had the same effect when introduced into a
slightly larger fragment of the mDkk3 promoter containing both
the ‘‘BSAP’’ and ‘‘5aCON’’ binding sites (Fig. 4B). However,
when the ‘‘5aCON’’ site was mutated, the transcriptional
activation increased (Fig. 4B), which is in line with the EMSA
showing stronger binding of Pax6 to the probe when the
‘‘5aCON’’ site was mutated. Importantly, the deletion caused in
the ‘‘5aCON’’ binding site by replacement of ten central
nucleotides with TT inhibited transcriptional activation by
Pax6/Pax6(5a) (Fig. 4B). The co-transfected plasmids used in the
reporter gene assays encode full-length Pax6 and Pax6(5a)
proteins, while only the recombinant Pax6 PD or Pax6(5a) PD
was used in EMSA. To see if the full-length Pax6- and Pax6(5a)
proteins had been able to bind the ‘‘BSAP’’ and ‘‘5aCON’’
binding sites, nuclear extracts from the FlpIn-3T3 Control, -Pax6
or -Pax6(5a) cell lines were used in EMSA. Since it turned out that
many proteins (also from the FlpIn-3T3 Control cell line) bound
these two probes in vitro (Fig. S1), we were unable to clarify the
contribution of Pax6 and Pax6(5a). Similar to the observed results
with the recombinant Pax6 PD, the mutated ‘‘BSAP’’ probe
bound less protein, while the mutated or optimized ‘‘5aCON’’
probe bound more protein than the wild type version of the probe.
Thus, the 50 bp sequence including the Pax6 binding ‘‘BSAP’’ site
just in front of TSS-2 seems to be a hot-spot for protein binding in
the mouse Dkk3 promoter. With that in mind it is remarkable that
transcriptional activation from this fragment in reporter gene
assays clearly required co-transfected Pax6 or Pax6(5a) (Fig. 3C
and Fig. 4C).
The FlpIn-3T3 Pax6 and -Pax6(5a) cell lines show
alterations in the Wnt signaling pathway compared to
the control cell line
To investigate whether the three generated FlpIn-3T3 cell lines
had differences in Wnt pathway activity, we performed a
TOPflash/FOPflash transfection and reporter gene assay. The
TOP reporter vector contains eight Tcf binding sites, and is
Figure 1. FlpIn-3T3 cells stably expressing Pax6 or Pax6(5a) have increased expression of Dkk3. A, RT-qPCR shows a 6-fold expression of
Dkk3 in the Pax6 cell line, and a 24-fold expression of Dkk3 in the Pax6(5a) cell line, compared to the untransfected FlpIn-3T3 control cell line. B,
Western blot confirms higher expression levels of Dkk3 protein in the two Pax6 containing cell lines. The observed molecular weight of Dkk3 is
between 60 and 70 kD due to glycosylation. For Pax6 it is 48 kD, Pax6(5a) 50 kD and for Actin 43 kD. C, Western blot of fractionated cell extracts
showing expression of Dkk3 and Pax6 (C; cytoplasm, N:E; nuclear extract, N.P; nuclear pellet). The nuclear pellet contains chromatin and remnants of
the cell membrane. D, confocal imaging of immunostained FlpIn-3T3Control, -Pax6 and -Pax6(5a) cells demonstrates that the Dkk3 protein is localized
in cytoplasm and nucleus. Draq5 (blue) was used to visualize the nuclei. Indicated scalebar = 20 mM.
doi:10.1371/journal.pone.0102559.g001
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responsive to activation of the Wnt pathway, by combined binding
of b-catenin and Tcf [34]. In the FOP reporter the Tcf sites are
mutated, so this vector should not be responsive to Wnt signaling.
However, we observed relatively high activity of both the TOP
and the FOP plasmid in the FlpIn-3T3 Pax6 cell line compared to
the control- and the FlpIn-3T3 Pax6(5a) cell lines before any
stimulation of the Wnt pathway (Fig. 5A). When LiCl was used to
activate the Wnt signaling pathway, the resulting normalized
TOP/FOP ratios showed that the FlpIn-3T3 Pax6- and Pax6(5a)
containing cell lines were 2–3 fold less responsive to the LiCl
stimulation compared to the control cell line (Fig. 5B). In principle,
this would fit with the theory that the cell lines expressing the
highest amount of Dkk3 would be less responsive to Wnt pathway
activation. Next we had a look at the levels of activated b-catenin.
All three FlpIn-3T3 cell lines were stimulated with 20 mM LiCl
30 minutes and 4 hours before harvesting. Four hours after LiCl
stimulation, there was far less active b–catenin in the FlpIn-3T3
Pax6(5a) cell line compared to both the FlpIn-3T3 Control and -
Figure 2. PAX6 regulates the expression of Dkk3 in several human cell lines derived from both normal and tumor tissues. A, RT-qPCR
of human cell lines where PAX6 has been knocked down either stably by shRNA (HPAFII), or transiently by siRNA (H460, H661 and GaMG). The result is
the mean of 3 independent experiments. B, Western blot of the pancreatic adenocarcinoma cell line HPAFII stably transfected with Pax6 shRNA. C,
Western blot of H460 and H661 (lung cancer), PC3 (prostate cancer), GaMG (glioblastoma) and B3 (normal lens epithelium) cell lines with transient
knockdown of PAX6 with siRNA. Each western blot in B and C is representative of at least two independent experiments. D, alignment of the human
and mouse Dkk3 promoter showing the localisation of the bioinformatically predicted and evolutionary conserved BSAP (Pax5)-, Pax6- and Pax6(5a)
binding sites. The start point for most transcripts in the mouse Dkk3 promoter is marked by an arrow (TSS-2). The human Dkk3/REIC promoter also
contains multiple transcripts initiating in this area according to DBTSS. 5aCONK is a Pax6(5a) consensus halfsite with 2 mismatches.
doi:10.1371/journal.pone.0102559.g002
Pax6 Regulates Dkk3 Expression
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e102559
Pax6 Regulates Dkk3 Expression
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e102559
Pax6 cell line, while the level of total b–catenin remained the same
in all three cell lines (Fig. 5C). It is known that activation of the
Wnt pathway causes an inhibitory phosphorylation of Ser 9 in
GSK3-b. This inhibition contributes to the stabilization and
activation of b–catenin. The Western blot in Fig. 5C clearly
showed that there is less GSK3-b Ser 9 phosphorylation in both
Figure 3. Both Pax6 and Pax6(5a) are potent activators of transcription of the minimal mouse Dkk3 promoter. A, the nucleotide
sequence of the 792 bp of the mouse Dkk3 promoter cloned into pGL3-basic. The SacI and PstI restriction enzyme sites used for truncation of the
promoter are indicated, along with the bioinformatically predicted binding sites for BSAP (Pax5), Pax6 and Pax6(5a). There are multiple transcriptional
start sites within a 40 bp area according to DBTSS. The arrow is placed at the peak of transcriptional initiation in the region called TSS-2. B, transient
transfection of a luciferase reporter vector containing the 792 bp fragment(2573/+219) from the mouse Dkk3 promoter in the FlpIn-3T3 Pax6(5a), -
Pax6 and -Control cell lines. The transfections were done in triplicates, and the figure shows one representative experiment of three in total. C, the
792 bp Dkk3 promoter reporter, 1(2573/+219) and deleted versions of it, 2 (2193/+219), 3 (29/+219), 4 (2573/29), 5 (2573/2193), 6 (-193/29) and
7 (pGL3-basic)., were co-transfected with Pax6 or Pax6(5a) expressing vectors in HeLa cells, identifying the minimal mouse Dkk3 promoter sequence
required for transcriptional activation by Pax6 and Pax6(5a). Transfections were done in triplicates, and co-transfection with pCH110 (b–gal) was used
to adjust for transfection efficiency. The figure shows mean values from 4–9 individual transfection experiments done in triplicates. The luc/b–gal
value from Dkk3 promoter construct number 1 co-transfected with Pax6 was set to 100%. The other results from co-transfection experiments with
deletion constructs, Pax6 and Pax6(5a) were compared to this. The mean and standard deviations were calculated, and the Student’s t-test showed
statistical significance (Fig. S3). D, The transfections done in HeLa cells were repeated in murine FlpIn-3T3 cells using the Lipofectamine 2000
transfection reagent. Transfections were done in triplicates, and co-transfection with pCH110 (b-gal) was used to adjust for transfection efficiency.
The figure shows a representative experiment of three in total.
doi:10.1371/journal.pone.0102559.g003
Figure 4. EMSA confirms direct binding by the Pax6 paired domain to an evolutionary conserved binding site in the mouse Dkk3
promoter, and a mutated version of this site is not longer able to mediate transcriptional activation by Pax6 from the Dkk3 promoter.
A, affinity purified recombinant GST-fusion proteins containing the Pax6- or the Pax6(5a) paired domain (PD) were used in EMSA with a 55 bp probe
covering the evolutionary conserved BSAP (Pax5) binding site in position 256/224 at the mouse Dkk3 promoter. A mutated version of this probe is also
included. The ‘‘5aCON’’ WT probe (position +180/+208 according to TSS-2), optimized (OPT) and mutated (MUT) versions of this probe were also used in
binding reactions with recombinant Pax6 PD and Pax6(5a) PD. The sequences of the wild type (WT) and mutated (MUT) ‘‘BSAP’’ probes are shown
beneath the gel. The exact localization of the three bioinformatically predicted- and overlapping BSAP sites is indicated by three lines above the ‘‘BSAP’’
probe sequence. The nucleotides changed in the ‘‘BSAP’’ MUT sequence are underlined. ‘‘5aCON’’ OPT is an optimized version, similar to the original
5aCON sequence. Grey bars show the homology with 5aCON for each version of the mouse Dkk3 ‘‘5aCON’’ probes. B, transient transfections and reporter
gene assays in HeLa cells with pGL3-mDkk3 promoter construct nr 2 (2193/+219) containing the mutated ‘‘BSAP’’ and ‘‘5aCON’’ sites, and a deleted
‘‘5aCON’’ site (‘‘5aCON D’’). The ten deleted nucleotides in the ‘‘5aCON D’’ probe which is replaced with the dinucleotide TT are indicated by a D symbol
above the sequence in A. C, transient transfections and reporter gene assays in HeLa cells with the minimal 184 bp pGL3-mDkk3 promoter construct, nr
6 (2193/29) containing the mutated ‘‘BSAP’’ site. Transfections were done as described in figure 3.
doi:10.1371/journal.pone.0102559.g004
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the FlpIn-3T3 Pax6 and -Pax6(5a) cell lines compared to the
control cell line four hours after LiCl stimulation. The level of total
GSK3-b was the same in all cell lines. This indicated that the
activation of the Wnt pathway was inhibited at the level of GSK3-
b in the FlpIn-3T3 Pax6 and -Pax6(5a) cell lines. This experiment
was repeated with the human HPAFII 13 (control) and HPAF II
84 (shRNA mediated PAX6 knockdown) cell lines, but we were
not able to see consistent changes in the level of activated b-
catenin or GSK3-b Ser 9 phosphorylation after 4 hrs of LiCl
stimulation (Fig. S2).
Dkk3 is reported to affect apoptosis and JNK signaling [29], and
JNK also plays a central role in activation of the non-canonical
Wnt pathway [42]. We therefore looked at the JNK expression
and phosphorylation in the three different 3T3 cell lines. UV-light
was used to induce stress. The results showed that JNK was slightly
more expressed in the FlpIn-3T3 Pax6 and -Pax6(5a) cells
compared to the FlpIn-3T3 Control cells, and so was the
activation measured by phospho-JNK (Fig. 5D). More phosphor-
ylation of JNK in the FlpIn-3T3 Pax6 and -Pax(5a) cell lines
probably only reflects the higher amount of JNK protein, and not
increased responsiveness to the stress signal.
Discussion
We have shown that Pax6 regulates the expression of Dkk3 in
cell lines derived from mouse and human. Dkk3 is positively
regulated by both the Pax6 and the Pax6(5a) isoforms in mouse
FlpIn-3T3 cells, and we have identified an evolutionary conserved
binding site for Pax6 immediately upstream of TSS-2 in the mouse
Dkk3 promoter. EMSA clearly showed the direct binding of the
Pax6 paired domain to this site. Other nuclear proteins were able
to bind this site as well, but for transcriptional activation Pax6
binding was essential. Since Dkk3 belongs to the Dickkopf family
of Wnt signaling pathway inhibitors, we investigated whether there
were differences in Wnt signaling pathway activity between the
FlpIn-3T3 Control cells (low Dkk3 expression) and the Pax6- and
Pax6(5a) expressing FlpIn-3T3 cells (high Dkk3 expression). Both
TOP/FOP reporter gene assay and Western blot of active b–
catenin and repressed GSK3-b showed differences between the
cell lines, indicating that the canonical Wnt pathway is indeed
affected.
There are various reports regarding the methylation status of
the Dkk3 promoter [26], and indications that histone modifica-
Figure 5. The FlpIn-3T3 Pax6 and Pax6(5a) cell lines display alterations in the Wnt signaling pathway compared to the FlpIn-3T3
control cell line. A, Transient transfections with the TOP and FOP reporter plasmids into the FlpIn-3T3 Control, Pax6 and Pax6(5a) cell lines, showing
basal (background) luc/b-gal activities. B, Calculations of TOP/FOP ratios as measures for Wnt signaling pathway response after transient transfections
and LiCl stimulation (20 mM) for 20 hours before harvesting of the three FlpIn-3T3 cell lines. C, Western blot of FlpIn-3T3 control, -Pax6 and -Pax6(5a)
cell lines serum starved for about 2 days before they were stimulated with LiCl (20 mM) and harvested after 30 minutes and after 4 hours. Antibody
against active b-catenin was first used and images were developed. The membrane was then stripped and antibodies against total b-catenin and
actin were used. Likewise, an antibody recognizing phosphorylated serine 9 in GSK3-b (inactivated) was first used, before antibodies against total
amount of GSK3-b and actin was applied to the same membrane. Results are representative of two biological replicates. D, The ability of the FlpIn-3T3
cell lines to phosphorylate JNK was investigated by Western blot after UV stimulation. Similar results were observed in three biological replicates.
doi:10.1371/journal.pone.0102559.g005
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tions may contribute to regulation of the promoter [29,30].
However, not much is known about transcription factors and
regulatory proteins binding to it. One study reports that p53 is
responsible for the increase in Dkk3 expression observed after
knockdown of Cdc7 and replication checkpoint arrest in a
fibroblast cell line [43]. These observed effects are not associated
with a particular binding site or region of the Dkk3 promoter. In
addition there are two recent studies showing that Dkk3 expression
is regulated by miRNA-92 in neuroblastoma cell lines [27,28].
Lately it was shown that Pax6 and Mitf enabled Wnt signaling in
the retina pigmented epitelial cells by repressing Dkk3 and Fgf19
[44]. A Pax6 binding site was identified in a distal enhancer, and
this mediated weak repression of the minimal Dkk3 promoter in
the ARPE19 (human retinal pigmented epithelial) cell line. In that
study the activity of the minimal promoter in combination with
Pax6 was not shown, so the results can therefore not be directly
compared to our findings.
Our results show that the regulation of Dkk3 by PAX6 takes
place in several cell lines from mouse and human. Since Dkk3 and
Pax6 are expressed in overlapping areas in both the brain and the
eye during embryo development [45,46], there is a possibility for
Dkk3 expression to be regulated by Pax6 in vivo in several tissues.
In support of this, Dkk3 was one of the downregulated genes in
Pax6 deficient telencephalon, indicating that Pax6 normally
upregulates Dkk3 expression in this tissue [47]. It seems to be
cell/tissue specific whether Pax6 activates or represses Dkk3
expression, and this is in line with what we observed in our
experiments. The fact that a gene can be regulated in opposite
directions by Pax6 in different tissue is also observed by others
[10].
While other members of the Dickkopf family (Dkk1, Dkk2 and
Dkk4) have been shown to bind LRP5/6 and function as Wnt
pathway inhibitors [19], the function of Dkk3 is somewhat more
enigmatic. Dkk3’s interaction with Krm takes place on intracel-
lular membranes located in the perinuclear region (possibly ER) in
HEK293 and SH-SY5Y cells, and in these cells Dkk3 leads to
activation, not inhibition, of Wnt signaling [20]. This observation
was recently confirmed in the reprogramming of embryonic lung
fibroblasts to smooth muscle cells where Dkk3 plays a central role
[48]. Contradictory to this, Dkk3 is reported to function as an
inhibitor of Wnt signaling, either by associating with bTrCP and
blocking b–catenin from entering the nucleus (as seen in HeLa
cells) [38], or by increasing the localisation of b–catenin in the cell
membrane, as seen in osteosarcoma cells [21]. We found less
active b-catenin and observed less TOP/FOP reporter gene
activity in the FlpIn-3T3 Pax6- and Pax6(5a) cell lines (compared
to the control cell line) after stimulation of the Wnt pathway with
LiCl. This supports the idea that Dkk3 in the 3T3-fibroblast cell
line functions as an inhibitor of the Wnt pathway. However, since
we (this work) and others [44,47] have shown that Pax6 can
enhance or repress Dkk3 expression, and since Dkk3 can enhance
or repress Wnt signaling through the canonical pathway depend-
ing on the cell type, it will be important for future studies to reveal
whether there is a correlation between Pax6 regulation of Dkk3
and the net effect this has on the Wnt pathway.
There are several reports on interactions between Pax6 and the
Wnt pathway. Pax6 regulates the expression of several Wnt
pathway components, both in the brain [49] and in the eye [15]. It
is also known that the Wnt signaling pathway is able to influence
Pax6 expression [50,51]. Since the Wnt pathway inhibitors Sfrp1
and Dkk1 are upregulated by Pax6 [15], it is possible that the
observed inhibition of Wnt pathway activation by LiCl in the
Pax6- and Pax6(5a) containing 3T3 cell lines can be caused by
factors other than Dkk3. Nevertheless, we have shown that the
presence of Pax6 and Pax6(5a) in FlpIn-3T3 cells makes these cells
less responsive to activation of the Wnt pathway.
Materials and Methods
Cell culture
FlpIn-3T3 cell lines (R761–07, Invitrogen, Life Technologies,
Carlsbad, CA) were grown in Dulbecco’s Modified Eagles
Table 2. Qiagen Quantitect primer assays.
Gene symbol Assay name Cat.No Amplicon length (bp) RefSeq Accession Number
hTFRC Hs_TFRC_1_SG QT00094850 81 NM_001128148 NM_003234
hGUSB Hs_GUSB_1_SG QT00046046 96 NM_000181
mTfrc Mm_Tfrc_1_SG QT00122745 106 NM_011638
Abbreviation: h; human, m; mouse TFRC; Transferrin receptor, GUSB; Glucuronidase beta.
doi:10.1371/journal.pone.0102559.t002
Table 1. Primers for RT-qPCR.
Gene symbol Forward primer (59-39) RT5 Reverse primer (59-39) RT3
Amplicon length
(bp) RefSeq Accession Number
hDKK3 CTGGGAGCTAGAGCCTGATG TCATACTCATCGGGGACCTC 168 NM_015881.5 NM_013253.4
NM_001018057.1
hPAX6 CAACTCCATCAGTTCCAACG TGGATAATGGGTTCTCTCAAACTCT 145 NM_001604.4 NM_000280.3
NM_001127612.1
mDkk3 GCAGCTGCTAAAACGTCCTC GACCACCTGTCCACTCTGGT 153 NM_015814.2
mNono TGGAAAAGCAGGCGAAGTTT TTTCCGCTAGGGTTCGTGTT 80 NM_023144.2
NM_001252518.1
Abbreviations: h; human, m; mouse, DKK3; Dickkopf 3, Nono; Non-POU-domain-containing octamer binding protein.
doi:10.1371/journal.pone.0102559.t001
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Medium (DMEM) - high glucose (Sigma-Aldrich, St.Louis, MO)
supplemented with 10% fetal calf serum (FCS) (Biochrom AG,
Berlin, Germany) supplemented with the appropriate antibiotics,
see [9] for construction of the cell lines. The human pancreatic
adenocarcinoma cell line HPAFII (ATCC CRL-1997, Rockville,
MD) was cultured in Eagle’s minimum essential medium (MEM)
(Sigma-Aldrich) with 10% FCS (Biochrom AG, Berlin, Germany).
The human glioblastoma cell lines GaMG [31], U-251 MG
(cat#09063001, Sigma-Adrich) and U-87 MG (ATCC HTB-14)
were grown in Dulbecco’s Modified Eagles Medium - high glucose
(Sigma-Aldrich) with 10% FCS (Biochrom AG). PC3 human
prostate cancer cells (ATCC CRL-1435) were cultured in F-12K
medium (cat#211-27, Gibco, Life Technologies, Carlsbad, CA)
with 10% FCS. Human large cell lung carcinoma cell lines NCI-
H661 (ATCC HTB-183) and NCI-H460 (ATCC HTP-177) were
grown in RPMI-1640 (Sigma-Aldrich) with 10% FCS. The human
lens epithelial cell line B3 (ATCC CRL-11421) was grown in
MEM supplemented with 2 mM L-glutamine, 0.1 mM non-
essential amino acids, 1 mM Sodium-puryvate and 20% FCS,
while human cervical carcinoma cell line HeLa (ATCC CCL2)
was grown in MEM supplemented with 2 mM L-glutamine, non-
essential amino acids and 10% FCS. Media for all cell lines
contained 1% of mixed 100 U/ml penicillin and 100 mg/ml
streptomycin (cat#P0781, Sigma-Aldrich).
Stimulation of cells with UV-light and LiCl
Cells seeded in 6-well plates were UV-stimulated for 15 minutes
using a single UV benchtop transilluminator (UVP, Upland, CA),
harvested by washing with PBS, adding 100 ml 2x SDS per well,
scraped, transferred to 1,5 ml tubes and immediately heated at
100uC for 5–10 minutes. For LiCl stimulation, cells were serum
starved in 6-well dishes for approximately 48 hours before LiCl
was added to a final concentration of 20 mM. Cells were harvested
after 30 minutes and after 4 hours as described above.
RNA interference
Cells were transfected in 6-well plates with human PAX6
siRNA (#114168 Silencer Select PAX6 siRNA, Ambion) using
Lipofectamine 2000 (#11668-027, Invitrogen). A scrambled
negative control siRNA was included in all experiments (Silencer
Negative Control #2 siRNA, Ambion). Cells were harvested
48 hrs after siRNA transfection.
29 mer HuSH shRNA constructs were purchased from Origene
(TG310597, Rockville, MD). Lipofectamine 2000 was used to
transfect the HPAFII cell line with either a construct targeting
Pax6 (84A) or a non-silencing control construct (13A). Cells with
stably integrated shRNA constructs were selected in growth
medium containing 1 mg/ml puromycin (Sigma-Aldrich) for
several passages. Knockdown of Pax6 in HPAFII 84A was verified
by Western blot and RT-qPCR.
RNA extraction and RT-qPCR
Total RNA was extracted using the RNeasy Plus kit (#74134,
Qiagen, Hilden, Germany). Reverse transcription of total RNA
was performed with Superscript III Reverse Transcriptase kit
(#18080-044, Invitrogen), using 150 ng random hexamer primers
(Fermentas International Inc., Canada). dNTP mix was purchased
from Promega (Madison, WI). We used 500 ng total RNA per
20 ml cDNA reaction. Primer pairs were designed using Primer 3
software (Whitehead Institute, Cambridge, MA) and synthesized
by Invitrogen or Sigma, or purchased directly from Qiagen (table
1 and 2). For quantification of mRNA expression levels, a
Stratagene MX3000P instrument (Stratagene, La Jolla, CA) was
used. cDNA corresponding to 25 ng RNA was amplified for 40
cycles in a 25 ml SYBR green PCR mix (Brilliant II SYBR Green
QPCR master mix, Stratagene) containing 200 nM of each
primer. Cycling conditions were as follows: 95uC for 10 min
followed by 40 cycles at 95uC for 30 sec, 60uC for 1 min and 72uC
for 30 sec. Duplicate PCR analyses were performed on each
cDNA sample. The absence of genomic DNA and contaminations
were confirmed by the inclusion of no reverse transcriptase (No
RT) controls and no template controls (NTCs) respectively. The
relative amount of target gene normalized to the average
expression of the two human reference genes GUSB and TFRC,
or the two mouse reference genes Nono and Tfrc, was determined
using the DDCq-method [32].
Preparation of nuclear extracts for Western blot
Cells were grown to 70–80% confluency in two 175 cm2 bottles,
trypsinized and harvested. After washing with PBS cells were
incubated with one packed cell volume (1 pcv) buffer A (10 mM
Tris HCl (pH 8), 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT)
containing protease inhibitors (cat#11 836 153 001, Roche
Diagnostics, Mannheim, Germany) for 15 min on ice. Cells were
crushed by 8 rapid strokes using a 1 ml syringe with a 25 g needle
and centrifuged for 20 sec at .130006g (4uC). The supernatant
was transferred to a separate tube (cytoplasm), while the pellet
containing the nuclei was resuspended in 2/3 pcv of buffer C
(50 mM Tris HCl (pH 8), 0.42 M KCl, 5 mM MgCl2, 0.1 mM
EDTA, 20% Glycerol, 10% Sucrose, 1 mM DTT) with protease
inhibitors, and cooled at 4uC for 30 min before centrifugation for
5 min at .130006g (4uC). The supernatant containing nuclear
extract was transferred to a separate tube. The nuclear pellet (the
insoluble remnants) was saved for later analyses. The BioRad
Table 3. Oligonucleotides used in EMSA and in vitro mutagenesis.#
mDkk3 ‘‘BSAP’’ WT CATCTGGGGGCGGGCAGAGCAGCGGGGCGGGGCGGGACGGGCAAGAGGGG
mDkk3 ‘‘BSAP’’ MUT CATCTGGGGGCGCCCAGATCATCAATTCGGAACGCTCCGGGCAAGAGGGG
mDkk3 ‘‘5aCON’’ WT GGAGGAAGCTACGCTCAATGAGATGTTTCGAGAGGTGGAGGAG
mDkk3 ‘‘5aCON’’ OPT GGAGGAAGCTATGCTCAGTGAGATGTTCATTGAGGTGGAGGAG
mDkk3 ‘‘5aCON’’ MUT GGAGGAAGCTACCCTGTATCCGATTTTTCGAGAGGTGGAGGAG
mDkk3 ‘‘5aCON’’ DEL CCCTCAGGAGGAAGCTACTTATGTTTCGAGAGGTGGAGG
5aCON ATCTGAACATGCTCAGTGAATGTTCATTGACTCTC
P6CON TGGAATTCAGGAAAAATTTTCACGCTTGAGTTCACAGCTCGAGTA
#The reverse complement of each oligonucleotide was also ordered.
doi:10.1371/journal.pone.0102559.t003
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reagent (#500-0006, BioRad Laboratories) was used to determine
the protein concentration. Fifteen mg were loaded on a SDS-
PAGE gel for western blot. The nuclear pellet was resuspended
and boiled in 2x SDS gel loading buffer, and 1/5 of the volume
was put on the gel.
Western blot
Prepared protein samples were run on a 10% SDS-PAGE gel
(Mighty Small, Invitrogen), and blotted onto a Hybond nitrocel-
lulose membrane (GE Healthcare) using the Mighty Small blotting
system (Invitrogen). The membrane was incubated with blocking
buffer (PBS buffer/0.1% Tween-20/5% non-fat dried milk).
Alternatively, samples were run on NuPAGE Novex 4–12% Bis-
Tris gels (Invitrogen), and blotted onto the Odyssey nitrocellulose
membrane (LI-COR Biosciences, Lincoln, NE). Membranes were
blocked using Odyssey blocking buffer (LI-COR Biosciences).
Primary and secondary antibodies were diluted in the blocking
buffer (20 ml Tween-20 added per 5 ml of the Odyssey blocking
buffer), and membranes were incubated over night at 4uC, or at
room temperature for at least 1 hour. Washing was done 5 times
for 5 minutes in PBS or TBS containing 0.1% Tween-20 after
each antibody incubation. Hybond membranes were incubated
with HRP-conjugated secondary antibodies, and developed using
the Western Blotting Luminol Reagent (sc-2048, Santa Cruz,
Dallas, TX). Images were acquired on an Image Reader LAS-
3000 Fujifilm. The LI-COR membranes were incubated with
IRDye Coupled secondary antibodies, and images were acquired
with the Odyssey Sa Infrared Imaging System (LI-COR Biosci-
ences).
Antibodies used were rabbit anti-Pax6 antibody 1:1200
(AB2237, Merck Millipore, Billerica, MA,), rabbit anti-Actin
1:2000 (A2066, Sigma-Aldrich), goat anti-Dkk3 1:4000 (ab2459,
Abcam), rabbit anti-phospho-JNK 1:1000 (#9251, Cell Signaling
Technology, Beverly, MA), rabbit anti-JNK 1:1000 (#9252, Cell
Signaling Technology), mouse anti-active b-catenin 1:2500 (#05-
665, Merck Millipore), rabbit anti-b-catenin 1:4000 (ab6302,
Abcam), anti-GSK3b-Ser9 1:1000 (#9322, Cell Signaling Tech-
nology), anti-GSK3b-total 1:500 (sc-9166, Santa Cruz Biotech-
nology), anti-rabbit HRP-conjugate 1:2000 (#554021, BD Bio-
sciences, San Jose, CA), anti-biotin HRP-linked antibody 1:2000
(#7075, Cell Signaling Technology). IRDye secondary antibodies:
anti-goat 800 CW 1:10 000 or anti-rabbit 800 CW 1:10 000
(#926-32214 and #926-32213, LI-COR Biosciences). Molecular
weight markers used were Prestained Protein marker, Broad range
(#77077S NEB, Ipswich, MA), Biotinylated protein marker
(#7727, Cell Signaling Technology), SeeBlue Plus2 Prestained
Standard (Invitrogen) and MagicMark XP Western Protein
Standard (Invitrogen).
Construction of reporter gene plasmids containing the
Dkk3 promoter
The mouse Dkk3 promoter was amplified by PCR from 3T3
fibroblast genomic DNA using primers 59-AAAGG-
TACCGTCGTGACCAGATCCAGCTT-39(KpnI) and 59-
AAAAGATCTCATCAGCTCCTCCACCTCTC-39(BglII). The
PCR product (792 bp) was first cloned into pCR-TOPO vector
(Invitrogen), confirmed by sequencing, and then subcloned
utilizing the restriction sites KpnI and BglII to the pGL3-basic
vector ( = pGL3-mDkk3prom). This is construct number 1
containing 573 bp upstream, and 219 bp downstream of the
predicted TSS (2573/+219). Deletions from the 59 and 39 end of
this promoter construct were done using the internal SacI and PstI
restriction sites in combination with either KpnI or BglII, followed
by agarose gel purification and self-ligation of the truncated pGL3-
mDkk3prom vector (construct 2–6 in Fig. 3C). The content of
each construct relative to the TSS is as follows: 2 (2193/+219), 3
(29/+219), 4 (2573/29), 5 (2573/2193) and 6 (2193/29). All
constructs were verified by sequencing.
In vitro mutagenesis
The pGL3 plasmid containing mDkk3 promoter construct nr 2
was used as template to mutate the ‘‘BSAP’’ site, and to mutate
and delete the ‘‘5aCON’’ site. In addition, the ‘‘BSAP’’ site
mutation was also introduced into the pGL3 plasmid containing
mDkk3 promoter construct nr 6. In vitro mutagenesis reactions
were performed by the use of primers containing the specific
mutations (see Table 3) in PCR reactions with Pfu Ultra High-
Fidelity DNA polymerase (Agilent Technologies) according to the
manufacturs instruction. PCR products were treated for one hour
with DpnI at 37uC before they were transformed into competent
E.coli DH5a cells. All mutations were verified by sequencing.
Reporter gene assay
HeLa cells were seeded at a density of 66104 cells per well in a
6-well dish the day before transfection with Lipofectamine 2000.
Each well contained 0.4 mg of the pKW-Pax6(5a), pKW-Pax6
[33], or the empty plasmid pKW10, in combination with 0.4 mg
reporter plasmid (pGL3-mDkk3promoter, construct 1–6) and
0.05 mg of the pCH110 plasmid (expressing b-galactosidase (b-
gal) for normalization of transfection efficiency). Harvesting was
done after 48 hours, and the Dual-Light System (T1003, Applied
Biosystems) was used for measurements of luciferase (luc) and b-gal
values on a Luminoskan RT dual injection luminometer
(Labsystems). All transfections were done in triplicates and
repeated 4–9 times. The mean luc/b-gal value for pKW-Pax6 in
combination with pGL3-mDkk3promoter (construct nr 1) was set
to 100% in each transfection, and then the luc/b-gal values
obtained for all the other constructs included in the same
transfection were related to this. For reporter gene assay
transfection in FlpIn-3T3 control cells the cells were seeded in
24 well dishes the day before transfection, and a total of 1,05 mg
DNA (0,5 mg reporter, 0,5 mg effector and 0.05 mg pCH110) and
2 ml Lipofectamine was used per well. For TOP/FOP Flash assays
FlpIn-3T3 Pax6, -Pax6(5a) and -control cells were seeded in 6-well
plates and transfected with 0.5 mg M50 Super 86TOPflash or
M50 Super 86FOPflash reporter plasmids per well (Addgene
plasmids 12456 and 12457, [34]) together with 0.05 mg pCH110
per well, using Lipofectamine 2000. 20 mM LiCl was added 24
hours after transfection, and harvesting was done after 24 hours as
described above. All transfections were done in triplicates and
repeated at least 3 times.
EMSA
The recombinant GST-Pax6 fusion proteins containing either
paired domain (PD), or paired domain with 14 amino acid insert
(PD5a) were used for protein-DNA interaction studies. GST-
fusion proteins were purified from Escherichia coli LE392 extracts
using glutathione-sepharose beads (#17-5132-01, Amersham
Biosciences, Little Chalfont, UK), and were eluted with 20 mM
reduced glutathion (G4251, Sigma-Aldrich). For probe generation,
6,25 ng of annealed probes were c32P–ATP (Perkin Elmer) labeled
with T4 polynucleotide kinase (#2021A, Takara Bio Inc, Tokyo,
Japan). Probe sequences are given in Table 3. Labeled probes were
purified using QIAquick Nucleotid Removal Kit (#28304,
Qiagen). The binding reaction was done essentially as described
in [35]. One microgram Poly(dI-dC) (#27-7880, Amersham
Biosciences) was used as nonspecific competitor per binding
reaction. Two mg of purified recombinant proteins or 10 mg of
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nuclear extracts were incubated with 20000 cpm probe for each
EMSA reaction. DNA-protein complexes were resolved on a 5%
TBE-based polyacrylamide gel. Gels were dried and exposed on
imaging plates overnight, and scanned at FUJI BAS-5000
analyzer.
Bioinformatic analyses
Identification of Pax6- and Pax6(5a) binding sites was done as
described in [9]. The database for transcriptional start sites
(DBTSS) [36] was used to identify transcriptional start sites in the
human and mouse Dkk3 genes.
Immunocytochemistry and confocal imaging
3T3 cells were seeded at a concentration of 2.46104 cells per
well into an 8-well chambered coverglass (#155411, Thermo
Scientific, Rochester, NY, US). The next day cells were fixed in
4% paraformaldehyde for 10 min on ice, permeabilized with ice-
cold methanol for 10 minutes on ice, and washed twice with PBS.
The cells were blocked in PBS with 3% goat or donkey serum for
60 min in room temperature. Cells were incubated with rabbit
anti-PAX6 antibody (AB2237, Merck Millipore), diluted 1:800 in
PBS with 1% goat serum, or goat anti-DKK3 antibody (ab2459,
Abcam), diluted 1:1000 in PBS with 1% donkey serum, for
30 minutes in RT. Cells were washed six times, incubated with
Alexa Fluor 488 goat anti-rabbit IgG, diluted 1:500 in PBS with
1% goat serum (A-11008, Invitrogen) or Alexa Fluor 488 donkey
anti-goat IgG, diluted 1:500 in PBS with 1% donkey serum (A-
11055) for 30 min in the dark. Cells were then washed four times,
and incubated for 10 minutes with DRAQ5 (1:1000 in PBS,
DR50200, Bio Status Limited, Leicestershire, UK). Cells were
washed four times and analyzed in the microscope. Images were
acquired with a Zeiss LSM 510 META confocal microscope and
the ZEN microscope software.
Supporting Information
Figure S1 The evolutionary conserved Pax6 (‘‘BSAP’’ and
‘‘5aCON’’) binding sites in the Dkk3 promoter are bound by
several nuclear proteins. Ten micrograms nuclear extracts from
FlpIn-3T3 Control, -Pax6 and -Pax6(5a) cell lines were used in
EMSA with the wild type and mutated versions of the ‘‘BSAP’’
and ‘‘5aCON’’ binding sites. The original P6CON [6], and
5aCON [2] probes are in vitro selected Pax6 and Pax6(5a)
binding sequences, and these were used as positive controls in the
panel to the right. The sequences of the probes are shown in Fig. 4.
(EPS)
Figure S2 HPAF II cells with normal and knocked down
expression of PAX6 show no consistent difference in Wnt pathway
activity upon LiCl stimulation. HPAF 13 (control) and HPAF 84
(PAX6 knocked down) cells were serum starved for 24 hours and
then stimulated with 20 mM LiCl for 4 hours before harvesting.
Western blotting with antibodies against active b-catenin, total b-
catenin, phosphorylated serine 9 of GSK3-b, total GSK3-b and
actin was done as described in Fig. 5C. Experiments 1–3 are three
biological replicates.
(EPS)
Figure S3 Statistical significance of the results obtained for the
transient transfection and reporter gene assays done in HeLa cells
with the various mDkk3 promoter fragments co-transfected with
Pax6 and Pax6(5a). The 792 bp Dkk3 promoter reporter and
deleted versions of it, were co-transfected with Pax6 or Pax6(5a)
expressing vectors in HeLa cells, identifying the minimal mouse
Dkk3 promoter sequence required for transcriptional activation by
Pax6 and Pax6(5a). Transfections were done in triplicates, and co-
transfection with pCH110 (b-gal) was used to adjust for
transfection efficiency. There were no differences in the overall
trend of which constructs did respond to Pax6/Pax6(5a) co-
transfection, and which did not, but the level of the response and if
it was Pax6 or Pax6(5a) that gave the best response varied. In this
case it was not possible to choose one experiment as ‘‘represen-
tative’’, so we increased the number of transfections and combined
the results of independent experiments. To be able to do this we
set the value obtained for the pGL3-mDkk3 promoter (construct
nr 1) co-transfected with Pax6 to 100% in each experiment, and
compared the result of all other transfections in that experiment to
this. Next, the mean percent values for all transfected construct
were calculated and presented as shown in Figure 3C. The
Student’s t-test (done in Excel, two-sided, assuming unequal
variance) showed significant differences for all but two of the
transfections when compared to the one given the 100% value.
(p,0.01, for 16 of the transfections, p,0.05 for two). The two
transfection which was not significantly different (#) had values
both higher and lower than 100% in a total of 7 and 8 different
transfection experiments. The figure shows mean values and
standard deviations from 4–9 independent experiments done in
triplicates for each construct.
(EPS)
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